Vanda Pharmaceuticals to Participate in Upcoming Investor Conferences
ROCKVILLE, Md., Feb. 23, 2012 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: VNDA), a biopharmaceutical company focused on the development and commercialization of products for the treatment of central nervous system disorders, today announced that it will participate in three upcoming investor conferences.
On Tuesday, February 28, 2012, Mihael Polymeropoulos, M.D., Vanda's President and CEO, will participate in a Neurology-focused discussion at RBC Capital Markets' Global Healthcare Conference in New York City.
On Wednesday, February 29, 2012, Dr. Polymeropoulos will deliver a corporate presentation at Citi's 2012 Global Health Care Conference at 2:00 pm Eastern Time in New York City.
The Citi conference presentation will be available live on Vanda's corporate website, where it will be archived for 30 days. To access this presentation, log on to http://www.vandapharma.com and click on the "Presentations" option in the Investor Relations section. Please connect to the website several minutes prior to the start of the live presentation.
On Monday, March 5, 2012, Dr. Polymeropoulos will deliver a corporate presentation at Cowen and Company's 32nd Annual Health Care Conference in Boston.
About Vanda Pharmaceuticals Inc.
Vanda Pharmaceuticals Inc. is a biopharmaceutical company focused on the development and commercialization of products for the treatment of central nervous system disorders. For more on Vanda Pharmaceuticals Inc., please visit http://www.vandapharma.com.
Senior Communications Manager
Vanda Pharmaceuticals Inc.
SOURCE Vanda Pharmaceuticals Inc.
More by this Source
Vanda Pharmaceuticals Reports Fourth Quarter 2013 and Full Year 2013 Results
Feb 13, 2014, 07:00 ET
FDA Approves HETLIOZ™ (tasimelteon) for the Treatment of Non-24-Hour Sleep-Wake Disorder
Jan 31, 2014, 13:45 ET
Browse our custom packages or build your own to meet your unique communications needs.
Learn about PR Newswire services
Request more information about PR Newswire products and services or call us at (888) 776-0942.